WSJ: “A bid by India’s Sun Pharmaceutical Industries Ltd. to acquire Swedish drug maker Meda AB for as much as $5 billion, could be a big plus for Sun, say stock analysts in India.
Mumbai-based Sun Pharma, which makes generic versions of patented drugs including those used for cancer treatment, has been the best performer on India’s benchmark Sensex’s 30-share index this year.
The stock has gained 42% this year to close at 1045.50 rupees ($18.45) a share on Friday. In comparison, Sensex is up only around 3% since the beginning of the year.
Analysts say a big acquisition that expands Sun Pharma’s product offerings would help it grow further. Already, Sun Pharma generates more than 70% of its total revenue from overseas units.”
via Sun Pharma Keeps Expanding Overseas – India Real Time – WSJ.
CHINDIA ALERT: You'll be living in their world, very soon 